FR15C0047I1 - - Google Patents

Info

Publication number
FR15C0047I1
FR15C0047I1 FR15C0047C FR15C0047I1 FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1 FR 15C0047 C FR15C0047 C FR 15C0047C FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0047(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0047I1 publication Critical patent/FR15C0047I1/fr
Application granted granted Critical
Publication of FR15C0047I2 publication Critical patent/FR15C0047I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR15C0047C 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine Active FR15C0047I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (2)

Publication Number Publication Date
FR15C0047I1 true FR15C0047I1 (enrdf_load_html_response) 2015-08-28
FR15C0047I2 FR15C0047I2 (fr) 2016-05-06

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0047C Active FR15C0047I2 (fr) 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine

Country Status (33)

Country Link
US (3) US7304078B2 (enrdf_load_html_response)
EP (5) EP1982984B1 (enrdf_load_html_response)
JP (2) JP4558331B2 (enrdf_load_html_response)
KR (1) KR101026929B1 (enrdf_load_html_response)
CN (1) CN1659162B (enrdf_load_html_response)
AR (1) AR039570A1 (enrdf_load_html_response)
AT (3) ATE378330T1 (enrdf_load_html_response)
AU (1) AU2003221932B2 (enrdf_load_html_response)
BR (1) BRPI0309309B8 (enrdf_load_html_response)
CA (1) CA2482858C (enrdf_load_html_response)
CY (3) CY1107184T1 (enrdf_load_html_response)
DE (3) DE60331114D1 (enrdf_load_html_response)
DK (2) DK2065384T3 (enrdf_load_html_response)
EC (1) ECSP045368A (enrdf_load_html_response)
ES (3) ES2297150T7 (enrdf_load_html_response)
FR (1) FR15C0047I2 (enrdf_load_html_response)
IL (1) IL164585A (enrdf_load_html_response)
LT (1) LTC1495018I2 (enrdf_load_html_response)
LU (1) LU92759I2 (enrdf_load_html_response)
MX (1) MXPA04010308A (enrdf_load_html_response)
MY (1) MY144040A (enrdf_load_html_response)
NL (1) NL300746I1 (enrdf_load_html_response)
NO (2) NO330500B1 (enrdf_load_html_response)
NZ (2) NZ535880A (enrdf_load_html_response)
PE (1) PE20040412A1 (enrdf_load_html_response)
PL (1) PL214718B1 (enrdf_load_html_response)
PT (2) PT1495018E (enrdf_load_html_response)
RU (2) RU2329264C9 (enrdf_load_html_response)
SG (1) SG164279A1 (enrdf_load_html_response)
SI (2) SI2065384T1 (enrdf_load_html_response)
TW (1) TWI343919B (enrdf_load_html_response)
WO (1) WO2003089428A1 (enrdf_load_html_response)
ZA (1) ZA200408342B (enrdf_load_html_response)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
CA2567981C (en) * 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
CA2582353A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
RS52117B (en) * 2005-01-14 2012-08-31 Schering Corporation DIASTEREO-SELECTIVATE SYNTHESIS OF EGZO ANALOGUE IN HIMBAC
EP1853592B1 (en) * 2005-01-14 2011-03-02 Schering Corporation Synthesis of himbacine analogs
CN101137636A (zh) * 2005-01-14 2008-03-05 先灵公司 Himbacine类似物的外型选择性合成
JP2008526254A (ja) * 2005-01-14 2008-07-24 シェーリング コーポレイション ヒンバシン類似物のキラルプロパルギルアルコールおよびエステル中間体の調製
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
CN101146781A (zh) * 2005-03-31 2008-03-19 先灵公司 螺环凝血酶受体拮抗剂
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
CN101384259A (zh) * 2005-12-22 2009-03-11 先灵公司 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
CN101466704A (zh) 2006-04-13 2009-06-24 先灵公司 稠合环凝血酶受体拮抗剂
AU2007269830A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US8153664B2 (en) * 2006-10-04 2012-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
KR20090058583A (ko) * 2006-10-04 2009-06-09 쉐링 코포레이션 힘바신의 개질된 트리사이클릭 단위를 기본으로 하는 트롬빈 수용체 길항제
WO2008079260A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
MX2009010268A (es) * 2007-03-23 2009-11-09 Schering Corp Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
ATE537172T1 (de) 2008-02-05 2011-12-15 Sanofi Sa Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
MY148732A (en) 2008-02-05 2013-05-31 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
PE20091972A1 (es) 2008-05-19 2010-01-15 Schering Corp Compuestos heterociclicos como inhibidores del factor ixa
JP5789256B2 (ja) 2009-06-04 2015-10-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． トロンビン受容体アンタゴニストの活性代謝物
EP2440191A2 (en) 2009-06-08 2012-04-18 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
EP2558462B1 (de) 2010-04-16 2014-10-22 Sanofi Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren
EP2558465B1 (de) 2010-04-16 2014-12-17 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
EP2822557B1 (en) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
WO2015026686A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
WO2015026693A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017181993A1 (zh) * 2016-04-22 2017-10-26 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CA3189771A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (enrdf_load_html_response) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
GB9102862D0 (en) * 1991-02-11 1991-03-27 Erba Carlo Spa N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
ES2219919T3 (es) * 1997-11-25 2004-12-01 Schering Corporation Antagonistas del receptor de trombina.
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
ES2291323T3 (es) * 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
AR036832A1 (es) * 2001-10-18 2004-10-06 Schering Corp Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos

Also Published As

Publication number Publication date
EP2062890B1 (en) 2011-01-05
EP1982984B1 (en) 2013-02-13
AR039570A1 (es) 2005-02-23
AU2003221932A1 (en) 2003-11-03
CA2482858A1 (en) 2003-10-30
JP2005528406A (ja) 2005-09-22
IL164585A (en) 2010-11-30
ES2297150T7 (es) 2012-03-16
CN1659162A (zh) 2005-08-24
ES2297150T3 (es) 2008-05-01
US7304078B2 (en) 2007-12-04
HK1123302A1 (en) 2009-06-12
EP2065384A1 (en) 2009-06-03
RU2329264C9 (ru) 2009-04-20
DK2065384T3 (da) 2011-05-02
LTC1495018I2 (lt) 2017-04-10
PE20040412A1 (es) 2004-07-12
ATE378330T1 (de) 2007-11-15
US20070270439A1 (en) 2007-11-22
HK1129893A1 (en) 2009-12-11
JP2010132710A (ja) 2010-06-17
US20070179187A1 (en) 2007-08-02
HK1070887A1 (en) 2005-06-30
CY1111363T1 (el) 2015-08-05
DK1495018T3 (da) 2008-02-18
CN1659162B (zh) 2011-08-31
DE60317493T2 (de) 2008-09-18
LU92759I2 (en) 2015-08-31
EP2062890A1 (en) 2009-05-27
EP2065384B1 (en) 2011-01-05
EP1860106B1 (en) 2010-01-20
NZ575139A (en) 2010-08-27
FR15C0047I2 (fr) 2016-05-06
NL300746I2 (enrdf_load_html_response) 2016-01-21
DE60331114D1 (de) 2010-03-11
TWI343919B (en) 2011-06-21
DE60317493D1 (en) 2011-01-13
US20030216437A1 (en) 2003-11-20
SG164279A1 (en) 2010-09-29
ATE494284T1 (de) 2011-01-15
PL373332A1 (en) 2005-08-22
ES2357876T3 (es) 2011-05-03
EP1982984A2 (en) 2008-10-22
EP1982984A3 (en) 2008-10-29
CY2015029I2 (el) 2016-04-13
NL300746I1 (enrdf_load_html_response) 2016-01-21
MXPA04010308A (es) 2005-02-03
KR20040099441A (ko) 2004-11-26
JP4558331B2 (ja) 2010-10-06
PT1495018E (pt) 2008-02-19
CY1107184T1 (el) 2012-10-24
CA2482858C (en) 2010-11-30
SI1495018T1 (sl) 2008-04-30
RU2008106401A (ru) 2009-08-27
EP1495018B1 (en) 2007-11-14
BRPI0309309B8 (pt) 2021-05-25
MY144040A (en) 2011-07-29
TW200404068A (en) 2004-03-16
EP1495018A1 (en) 2005-01-12
ATE455774T1 (de) 2010-02-15
US7713999B2 (en) 2010-05-11
ECSP045368A (es) 2005-01-03
WO2003089428A1 (en) 2003-10-30
NO2015016I2 (no) 2015-07-09
ZA200408342B (en) 2006-05-31
KR101026929B1 (ko) 2011-04-04
NO20044963L (no) 2004-11-15
IL164585A0 (en) 2005-12-18
BR0309309A (pt) 2005-02-15
NO330500B1 (no) 2011-05-02
AU2003221932B2 (en) 2007-11-22
PT2065384E (pt) 2011-03-16
EP1860106A1 (en) 2007-11-28
NO2015016I1 (no) 2015-07-20
ES2338171T3 (es) 2010-05-04
CY2015029I1 (el) 2016-04-13
SI2065384T1 (sl) 2011-05-31
BRPI0309309B1 (pt) 2018-09-04
DE60317493T3 (de) 2018-07-12
EP1495018B3 (en) 2011-03-16
RU2004133375A (ru) 2005-07-10
NZ535880A (en) 2007-11-30
RU2329264C2 (ru) 2008-07-20
DE60335679D1 (de) 2011-02-17
PL214718B1 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
BE2019C510I2 (enrdf_load_html_response)
BE2018C021I2 (enrdf_load_html_response)
BE2017C049I2 (enrdf_load_html_response)
BE2017C005I2 (enrdf_load_html_response)
BE2016C069I2 (enrdf_load_html_response)
BE2016C040I2 (enrdf_load_html_response)
BE2018C018I2 (enrdf_load_html_response)
BE2016C013I2 (enrdf_load_html_response)
BE2015C078I2 (enrdf_load_html_response)
BE2016C002I2 (enrdf_load_html_response)
FR15C0047I1 (enrdf_load_html_response)
BE2015C017I2 (enrdf_load_html_response)
BE2014C053I2 (enrdf_load_html_response)
BE2014C051I2 (enrdf_load_html_response)
BE2014C041I2 (enrdf_load_html_response)
BE2014C030I2 (enrdf_load_html_response)
BE2014C016I2 (enrdf_load_html_response)
BE2014C015I2 (enrdf_load_html_response)
BE2013C063I2 (enrdf_load_html_response)
BE2013C039I2 (enrdf_load_html_response)
BE2011C038I2 (enrdf_load_html_response)
JP2003188402A5 (enrdf_load_html_response)
JP2003190159A5 (enrdf_load_html_response)
BE2015C069I2 (enrdf_load_html_response)
JP2003182329A5 (enrdf_load_html_response)